uk-453-061 and Acquired-Immunodeficiency-Syndrome

uk-453-061 has been researched along with Acquired-Immunodeficiency-Syndrome* in 1 studies

Other Studies

1 other study(ies) available for uk-453-061 and Acquired-Immunodeficiency-Syndrome

Article	Year
Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate. Bioorganic & medicinal chemistry letters, 2009, Oct-15, Volume: 19, Issue:20 We prepared three discreet cohorts of potent non-nucleoside HIV reverse transcriptase inhibitors (NNRTIs) based on the recently reported 3-cyanophenoxypyrazole lead 3. Several of these compounds displayed very promising anti-HIV activity in vitro, safety, pharmacokinetic and pharmaceutical profiles. We describe our analysis and conclusions leading to the selection of alcohol 5 (UK-453,061, lersivirine) for clinical development. Topics: Acquired Immunodeficiency Syndrome; Animals; Anti-HIV Agents; Cell Line; Drug Resistance, Viral; HIV Reverse Transcriptase; Humans; Microsomes, Liver; Nitriles; Pyrazoles; Rats; Reverse Transcriptase Inhibitors	2009

Article

Year

Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate.

Bioorganic & medicinal chemistry letters, 2009, Oct-15, Volume: 19, Issue:20

We prepared three discreet cohorts of potent non-nucleoside HIV reverse transcriptase inhibitors (NNRTIs) based on the recently reported 3-cyanophenoxypyrazole lead 3. Several of these compounds displayed very promising anti-HIV activity in vitro, safety, pharmacokinetic and pharmaceutical profiles. We describe our analysis and conclusions leading to the selection of alcohol 5 (UK-453,061, lersivirine) for clinical development.

Topics: Acquired Immunodeficiency Syndrome; Animals; Anti-HIV Agents; Cell Line; Drug Resistance, Viral; HIV Reverse Transcriptase; Humans; Microsomes, Liver; Nitriles; Pyrazoles; Rats; Reverse Transcriptase Inhibitors

2009